HPK1-IN-7
CAS No. 2320462-65-3
HPK1-IN-7( —— )
Catalog No. M28709 CAS No. 2320462-65-3
HPK1-IN-7 is an orally active HPK1 inhibitor. It shows selectivity against IRAK4 (59 nM) and GLK (140 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 170 | In Stock |
|
| 5MG | 264 | In Stock |
|
| 10MG | 435 | In Stock |
|
| 25MG | 710 | In Stock |
|
| 50MG | 972 | In Stock |
|
| 100MG | 1341 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameHPK1-IN-7
-
NoteResearch use only, not for human use.
-
Brief DescriptionHPK1-IN-7 is an orally active HPK1 inhibitor. It shows selectivity against IRAK4 (59 nM) and GLK (140 nM).
-
DescriptionHPK1-IN-7 is an orally active HPK1 inhibitor. It shows selectivity against IRAK4 (59 nM) and GLK (140 nM).
-
In Vitro——
-
In VivoAnimal Model:Mice (MC38 syngeneic tumor model)Dosage:100 mg/kg Administration:Oral; twice daily for 28 days Result:Enhanced the efficacy of anti-PD1 treatment, garnering a 100% cure rate vs a 20% cure rate with anti-PD1 alone.
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
RecptorEndothelin-1 receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2320462-65-3
-
Formula Weight458.478
-
Molecular FormulaC24H22N6O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (272.65 mM)
-
SMILESCC1(C)OC(=O)c2ccc(Nc3ncc(-c4nnco4)c(N[C@H](CO)c4ccccc4)n3)cc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
UR13870
UR-13870 (Org 48762-0) is an orally active and selective inhibitor of p38 mitogen-activated protein kinase (MAPK), which prevents bone damage in collagen-induced arthritis in mice.
-
Bisabolangelone
Bisabolangelone has anti-tumor, anti-inflammatory, anti-microbial, and antioxidant activities, it inhibits dendritic cell functions by blocking MAPK and NF-κB signaling.Bisabolangelone (BISA), isolated from the roots of Angelica koreana, has many pharmacological activities, such as anti-tumor, anti-microbial, antioxidant, and anti-inflammatory activities.?
-
Darizmetinib
Darizmetinib (HRX215, HRX-0215) is an MKK4 inhibitor. Inhibition of MKK4 leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration.
Cart
sales@molnova.com